Cochrane review of 21 RCTs finds LiSWT may improve erectile function, but the short-term effect (MD 3.89 points) falls below the 4-point minimal clinically important difference — and all evidence is low certainty.
Journal: BJU International | Published: 2026-03-30 | Type: Systematic Review / Abridged Cochrane Review | PMID: 41906634 Authors: Ergun Onuralp et al. (University of Minnesota, Yonsei University, Chonnam National University, University of Michigan, Hacettepe University, Avant Concierge Urology) Funding/COI: Not listed
This abridged Cochrane review pooled 21 randomised controlled trials (1,357 men, ages 39–65) comparing low-intensity shockwave therapy to sham treatment for erectile dysfunction. LiSWT produced a mean short-term improvement of 3.89 points on the IIEF-EF scale — just below the pre-defined 4-point minimal clinically important difference. The long-term signal looks more promising (MD 5.25 points), but those results come from only five studies, all with unusually favorable short-term outcomes, and the heterogeneity is severe (I² = 87%). Every single outcome was rated low-certainty under GRADE.
This is a Cochrane review, which means the methodology is more rigorous than most: pre-specified PICO, registered protocol, GRADE certainty assessment, PRISMA reporting, and random-effects pooling. Those structural strengths matter. What they can't fix is the quality of the underlying trials. Almost every included RCT failed to describe allocation concealment, more than half had blinding problems (participants, personnel, and outcome assessors), and only two of twenty-one studies were conducted with a pre-registered protocol. That's a poor foundation for a meta-analysis, and the GRADE team downgraded all outcomes by two levels accordingly.
Heterogeneity is the other central problem. I² values of 62–89% across the erectile function outcomes mean the pooled mean differences are averaging across studies that may be measuring fundamentally different effects — different patient profiles, energy densities, treatment frequencies, and follow-up windows. The authors ran subgroup and sensitivity analyses and could not explain it.
This is a well-executed Cochrane review of badly-designed trials. The methodology of the review itself is sound — Cochrane does not publish sloppy work — but the 21 underlying RCTs are, by the review's own accounting, a mess: poor blinding, no allocation concealment, almost none pre-registered, and highly variable treatment protocols. The result is a low-certainty finding that LiSWT "may" improve erectile function, with the short-term effect landing just below clinical significance and the long-term effect contaminated by selective reporting. The adverse event profile is reassuringly clean. Whether the therapy actually works remains, after 21 trials and 1,357 patients, genuinely uncertain. That is the story here — not that shockwave therapy is hopeless, but that the field has spent a decade running underpowered, underprotocol studies and produced noise. The review's call for larger, standardised RCTs with pre-registered protocols is not a polite footnote; it is the only honest conclusion from this data.